The Role of Aquablation for the Surgical Treatment of LUTS/BPH
- 56 Downloads
Purpose of Review
To explore the potential applicability of a novel, heat-free, and robotically controlled ablative therapy for surgical management of benign prostatic enlargement.
With the emergence of new technology to provide personalized care and overcome the complications associated with options such as TURP, holmium laser enucleation of the prostate, GreenLight laser, or simple prostatectomy, Aquablation has been studied across a variety of prostate volumes.
The functional outcome of Aquablation seems to be uncompromised by prostate volume. The sexual profile seems superior to TURP and the risk of retrograde ejaculation is lower. The robotic system provides a reproducible ablation, independent of prostate volume, without requiring extensive training for performing the procedure. The mean ablation time in the prostate as large as 150 ml does not exceed 9.1 min, and the blood transfusion rates do not seem to be higher than open prostatectomy.
KeywordsLUTS BPH Aquablation Outcomes
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P, et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol. 2007;177(4):1395–400. https://doi.org/10.1016/j.juro.2006.11.065.
- 3.Oelke M, Bachmann A, Descazeaud A, et al. members of the EAU Guidelines Panel. EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO) E. Retreived from https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/. https://doi.org/10.1007/s10126-007-9056-7. Accessed Feb 2019.
- 4.Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017;24(3):8802–13 http://www.ncbi.nlm.nih.gov/pubmed/28646935. Accessed 25 Jan 2019.
- 5.Porpiglia F, Fiori C, Amparore D, Kadner G, Manit A, Valerio M, et al. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up. BJU Int. 2018;123:1061–9. https://doi.org/10.1111/bju.14608.
- 7.Desai M, Bidair M, Zorn KC, et al. Aquablation for BPH in large prostates (80-150cc): 6-month results from the WATER II trial. BJU Int. 2019;Feb (epub. doi: https://doi.org/10.1111/bju.14703.
- 8.Geavlete P. Is classical transurethral resection of the prostate, the gold standard endoscopic treatment for benign prostate hyperplasia, in real danger of being replaced? Eur Urol. 2010;58(3):356–8–9. https://doi.org/10.1016/j.eururo.2010.06.001.
- 10.• Gilling P, Barber N, Bidair M, et al. WATER: a double-blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. J Urol. 2018;199(5):1252–61. https://doi.org/10.1016/j.juro.2017.12.065 This is the first study comparing Aquablation to TURP.
- 12.Desai MM, Singh A, Abhishek S, Laddha A, Pandya H, Ashrafi AN, et al. Aquablation therapy for symptomatic benign prostatic hyperplasia: a single-centre experience in 47 patients. BJU Int. 2018;121(6):945–51. https://doi.org/10.1111/bju.14126.
- 13.Bach T, Giannakis I, Bachmann A, et al. Aquablation of the prostate: single-center results of a non-selected, consecutive patient cohort. World J Urol. 2018. https://doi.org/10.1007/s00345-018-2509-y.
- 14.•• Desai M, Bidair M, Bhojani N, et al. WATER II (80–150 ml) procedural outcomes. BJU Int. 2019;123:106–112. doi: https://doi.org/10.1111/bju.14360. This is the first study that did not allow prostates smaller than 80 ml to be enrolled and showed applicability of Aquablation in prostates largere than the suggested upper limit for TURP.
- 15.•• Bhojani N, Nguyen DD, Kaufman RP, et al. Comparison of < 100 cc prostates and > 100 cc prostates undergoing Aquablation for benign prostatic hyperplasia. World J Urol. 2018. doi: https://doi.org/10.1007/s00345-018-2535-9. This study also confirmed the applicability of Aquablation in large prastates.
- 18.Gilling P, Barber N, Bidair M, et al. Randomized controlled trial of Aquablation vs transurethral resection of the prostate in benign prostatic hyperplasia: one-year outcomes. Urology. 2018;125:169–73. https://doi.org/10.1016/j.urology.2018.12.002.
- 19.Plante M, Gilling P, Barber N, Bidair M, Anderson P, Sutton M, et al. Symptom relief and anejaculation after Aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial. BJU Int. 2018;123:651–60. https://doi.org/10.1111/bju.14426.
- 21.Zorn KC, Goldenberg SL, Paterson R, So A, Elterman D, Bhojani N. Aquablation among novice users in Canada: a WATER II subpopulation analysis. Can Urol Assoc J. 2019;13(5):E113–E118. https://doi.org/10.5489/cuaj.5501.
- 23.Valdivieso R, Hueber P-A, Meskawi M, Belleville E, Ajib K, Bruyere F, et al. Multicentre international experience of 532-nm laser photoselective vaporization with GreenLight XPS in men with very large prostates. BJU Int. 2018;122(5):873–8. https://doi.org/10.1111/bju.14208.